Physician profile
Chris Y Brunson
NPI 1235106337
$11,926.10
in general payments reported to CMS, 2019-2025
61 companies · $2,291 in 2025
The $2,291 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,337 · 2020: $1,093 · 2021: $1,641 · 2022: $2,296 · 2023: $1,428 · 2024: $1,840 · 2025: $2,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,259 · Long Term Medical Supply Or Device Loan: $2,079 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,258.98 |
| Long Term Medical Supply Or Device Loan | $2,078.81 |
| Education | $220.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,309.20 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $674.08 | 2019-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $630.70 | 2020-2025 | Calquence, Enhertu |
| Incyte Corporation | $501.15 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $474.06 | 2019-2025 | Enhertu, Injectafer, Datroway |
| E.R. Squibb & Sons, L.L.C. | $425.25 | 2019-2023 | Opdivo |
| Janssen Biotech, INC. | $415.63 | 2019-2025 | Erleada, Balversa, Akeega |
| Genentech USA, INC. | $412.53 | 2019-2024 | Venclexta, Perjeta, Phesgo |
| Glaxosmithkline, LLC. | $321.57 | 2020-2023 | Jemperli, Zejula |
| Penumbra, INC. | $291.70 | 2022-2025 | Indigo System |
| Celgene Corporation | $284.08 | 2021-2025 | Reblozyl, Pomalyst |
| Amgen INC. | $283.01 | 2019-2022 | |
| Genzyme Corporation | $266.91 | 2019-2025 | |
| Pfizer INC. | $246.56 | 2019-2025 | |
| Lilly USA, LLC | $223.88 | 2019-2023 | Verzenio |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Brunson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.